These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30226476)

  • 21. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
    Papastefanou VP; René C
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
    Fife K; Herd R; Lalondrelle S; Plummer R; Strong A; Jones S; Lear JT
    Future Oncol; 2017 Jan; 13(2):175-184. PubMed ID: 27640448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Successful therapy of metastatic basal cell carcinoma with vismodegib].
    Zutt M; Mazur F; Bergmann M; Lemke AJ; Kaune KM
    Hautarzt; 2014 Nov; 65(11):974-7. PubMed ID: 25217085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
    Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
    Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Merkel cell carcinoma and multiple basal cell carcinoma in an African albino woman with HIV infection.
    Colebunders R; Bottieau E; Van den Brande J; Colpaert C; Van Marck E
    HIV Med; 2004 Nov; 5(6):452-4. PubMed ID: 15544700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
    Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vismodegib in metastasized basal cell carcinoma].
    Reinders MG; Dirix L; Mosterd K; van Doorn R
    Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
    Yang X; Dinehart SM
    JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945
    [No Abstract]   [Full Text] [Related]  

  • 29. New perspectives in the management of basal cell carcinoma.
    Martín-Gorgojo A; Pastushenko I
    Actas Dermosifiliogr; 2014 Nov; 105(9):874-5. PubMed ID: 24934656
    [No Abstract]   [Full Text] [Related]  

  • 30. Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma.
    Paulsen JF; Øregaard JS; Nielsen AL; Gehl J; Venzo A
    Acta Oncol; 2016 Dec; 55(12):1492-1494. PubMed ID: 27448604
    [No Abstract]   [Full Text] [Related]  

  • 31. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
    Kaehler KC; Gutzmer R; Egberts F; Hauschild A
    J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
    [No Abstract]   [Full Text] [Related]  

  • 32. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management.
    Le Moigne M; Saint-Jean M; Jirka A; Quéreux G; Peuvrel L; Brocard A; Gaultier A; Khammari A; Darmaun D; Dréno B
    Support Care Cancer; 2016 Apr; 24(4):1689-95. PubMed ID: 26416491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sonic Hedgehog Pathway Blockade After Surgical Debulk of Large Exophytic Basal Cell Carcinomas.
    Wirth PJ; Hobbs R; Billingsley E; Vidimos AT; Lam C
    Dermatol Surg; 2021 Aug; 47(8):1118-1119. PubMed ID: 34107497
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
    Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
    Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib.
    Thomas CL; Arasaratnam M; Carlos G; Parasyn A; Baumgart KW; Fernandez-Penas P; Marx G
    Australas J Dermatol; 2017 Feb; 58(1):69-70. PubMed ID: 28195319
    [No Abstract]   [Full Text] [Related]  

  • 36. Four-year experience with vismodegib hedgehog inhibitor therapy.
    Simone PD; Schwarz JM; Strasswimmer JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
    [No Abstract]   [Full Text] [Related]  

  • 37. Vismodegib in advanced basal-cell carcinoma.
    Babacan T; Sarici F; Altundag K
    N Engl J Med; 2012 Sep; 367(10):969-70; author reply 970. PubMed ID: 22931270
    [No Abstract]   [Full Text] [Related]  

  • 38. Palliative Use of Vismodegib.
    Lam C; Larson E; Vidimos AT; Billingsley EM
    Dermatol Surg; 2020 Feb; 46(2):272-276. PubMed ID: 30789523
    [No Abstract]   [Full Text] [Related]  

  • 39. Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application.
    Tang JC; Hanke CW; Caro I
    J Drugs Dermatol; 2018 May; 17(5):506-508. PubMed ID: 29742180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
    Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.